ClinicalTrials.gov record
Terminated Phase 1 Interventional

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

ClinicalTrials.gov ID: NCT01088763

Public ClinicalTrials.gov record NCT01088763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA

Study identification

NCT ID
NCT01088763
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
129 participants

Conditions and interventions

Conditions

Interventions

  • dexamethasone Drug
  • diagnostic laboratory biomarker analysis Other
  • gamma-secretase/Notch signalling pathway inhibitor RO4929097 Drug
  • pharmacological study Other

Drug · Other

Eligibility (public fields only)

Age range
1 Year to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2010
Primary completion
Apr 30, 2011
Completion
Apr 30, 2011
Last update posted
Nov 4, 2014

2010 – 2011

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Lucile Packard Children's Hospital Stanford University Palo Alto California 94304
Stanford University Hospitals and Clinics Stanford California 94305
Lurie Children's Hospital-Chicago Chicago Illinois 60614
Indiana University Medical Center Indianapolis Indiana 46202
Dana-Farber Cancer Institute Boston Massachusetts 02115
Washington University School of Medicine St Louis Missouri 63110
Columbia University Medical Center New York New York 10032
Nationwide Children's Hospital Columbus Ohio 43205
St. Jude Children's Research Hospital Memphis Tennessee 38105
Baylor College of Medicine Houston Texas 77030
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01088763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2014 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01088763 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →